We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Athera and Medirista Sign Agreement


Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Athera and Medirista Sign Agreement"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:
 

Athera Biotechnologies AB has announced that the rights to the recombinant Annexin A5 have been transferred to Medirista AB.

Medirista is a biotech company owned by the original innovators of the Annexin A5 project, Johan and Anna Frostegård.

The whole patent portfolio together with key preclinical assets have been transferred. Athera will continue its focus on development of the lead product candidate, the fully human antibody in atherosclerosis.

Recombinant Annexin A5 has been developed to preclinical stage by Athera as an anti-inflammatory therapy, primarily targeting prevention of complications following vascular surgery.

Annexin A5 has been shown to beneficially affect remodelling in a preclinical model of coronary bypass grafting. Another study showed that low doses of Annexin A5 could prevent injury in a model mimicking catheter-based percutaneous interventions (PCI) in mice.

Millions of PCI procedures are done per year due to acute coronary syndrome (ACS) and the number is rapidly increasing.

Advertisement